Quantitative Investment Management LLC Takes Position in DexCom, Inc. $DXCM

Quantitative Investment Management LLC purchased a new position in DexCom, Inc. (NASDAQ:DXCM) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 27,549 shares of the medical device company’s stock, valued at approximately $1,855,000.

Other large investors have also recently made changes to their positions in the company. Ancora Advisors LLC raised its stake in DexCom by 354.0% in the 2nd quarter. Ancora Advisors LLC now owns 976 shares of the medical device company’s stock valued at $66,000 after purchasing an additional 761 shares during the last quarter. Two Sigma Securities LLC boosted its stake in DexCom by 173.6% during the 2nd quarter. Two Sigma Securities LLC now owns 8,895 shares of the medical device company’s stock worth $599,000 after purchasing an additional 5,644 shares during the last quarter. Flputnam Investment Management Co. acquired a new stake in DexCom during the 2nd quarter worth $1,058,000. Wedbush Securities Inc. grew its holdings in shares of DexCom by 9.7% during the second quarter. Wedbush Securities Inc. now owns 14,903 shares of the medical device company’s stock worth $1,004,000 after buying an additional 1,315 shares in the last quarter. Finally, Greenleaf Trust purchased a new stake in shares of DexCom during the second quarter worth $202,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Stock Up 0.3%

NASDAQ DXCM opened at $91.06 on Tuesday. The business’s fifty day simple moving average is $79.64 and its 200-day simple moving average is $71.77. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The firm has a market cap of $34.36 billion, a PE ratio of 35.99, a P/E/G ratio of 1.53 and a beta of 1.41. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $92.59.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. During the same quarter in the prior year, the firm posted $0.48 earnings per share. DexCom’s quarterly revenue was up 13.1% on a year-over-year basis. As a group, equities analysts anticipate that DexCom, Inc. will post 2.64 earnings per share for the current year.

Wall Street Analyst Weigh In

DXCM has been the topic of several research reports. UBS Group set a $96.00 price target on shares of DexCom and gave the stock a “buy” rating in a research note on Tuesday, July 28th. JPMorgan Chase & Co. upped their price objective on shares of DexCom from $65.00 to $82.00 and gave the company a “neutral” rating in a research note on Friday, July 31st. Wells Fargo & Company raised their target price on shares of DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Mizuho boosted their target price on DexCom from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Finally, Wall Street Zen lowered DexCom from a “buy” rating to a “hold” rating in a research report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.71.

Insider Buying and Selling

In other news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.55, for a total transaction of $128,435.00. Following the sale, the executive vice president owned 106,353 shares of the company’s stock, valued at approximately $8,034,969.15. The trade was a 1.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,912 shares of DexCom stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $73.00, for a total transaction of $358,576.00. Following the sale, the executive vice president directly owned 100,361 shares in the company, valued at approximately $7,326,353. The trade was a 4.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 75,600 shares of company stock worth $5,673,342 over the last ninety days. 0.28% of the stock is currently owned by insiders.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.